The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity
Abstract
Alterations to the tumor microenvironment following localized irradiation may influence the effectiveness of subsequent immunotherapy. The objective of this study was to determine how IFN-γ influences the inflammatory response within this dynamic environment following radiotherapy. B16/OVA melanoma cells were implanted into C57BL/6 (wild-type (WT)) and IFN-γ-deficient (IFN-γ−/−) mice. Seven days after implantation, mice received 15 Gy of localized tumor irradiation and were assessed 7 days later. Irradiation up-regulated the expression of VCAM-1 on the vasculature of tumors grown in WT but not in IFN-γ−/− mice. Levels of the IFN-γ-inducible chemokines MIG and IFN-γ-inducible protein 10 were decreased in irradiated tumors from IFN-γ−/− mice compared with WT. In addition to inducing molecular cues necessary for T cell infiltration, surface MHC class I expression is also up-regulated in response to IFN-γ produced after irradiation. The role of IFN-γ signaling in tumor cells on class I expression was tested using B16/OVA cells engineered to overexpress a dominant negative mutant IFN-γ receptor (B16/OVA/DNM). Following implantation and treatment, expression of surface class I on tumor cells in vivo was increased in B16/OVA, but not in B16/OVA/DNM tumors, suggesting IFN-γ acts directly on tumor cells to induce class I up-regulation. These increases in MHC class I expression correlated with greater levels of activated STAT1. Thus, IFN-γ is instrumental in creating a tumor microenvironment conducive for T cell infiltration and tumor cell target recognition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359 · cited 1×
“These two chemokines, along with the increased expression of MIP-1 , serve to attract T cells that express the receptors CXCR3 and CCR5 into inflamed tissues, including the irradiated tumors in our experiments (39).”
BackgroundDufour, J. H., Dziejman, M., Liu, M. T., Leung, J. H., Lane, T. E., & Luster, A. D. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.7.3195 · Cited by 1,075
Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · cited 4×
“Localized irradiation of tumor-bearing legs was performed as described previously (17).”
BackgroundMethodSelf-citationChemokines in tissue-specific and microenvironment-specific lymphocyte homing
Campbell, J. J., & Butcher, E. C. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00096-0 · Cited by 625
Cited by
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift
Formenti, S. C., & Demaria, S. (2013) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs629 · Cited by 1,053
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
Chemokines and the immune response to cancer
Ozga, A. J., Chow, M. T., & Luster, A. D. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.012 · Cited by 830
Role of Local Radiation Therapy in Cancer Immunotherapy
Demaria, S., Golden, E. B., & Formenti, S. C. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2756 · Cited by 779
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Maalej, K. M., Merhi, M., Inchakalody, V. P., Mestiri, S., Alam, M., Maccalli, C., Cherif, H., Uddin, S., Steinhoff, M., Marincola, F. M., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01723-z · Cited by 618
Maximizing Tumor Immunity With Fractionated Radiation
Schaue, D., Ratikan, J. A., Iwamoto, K. S., & McBride, W. H. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.09.049 · Cited by 567
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 566
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
Zappasodi, R., Merghoub, T., & Wolchok, J. D. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.005 · Cited by 525
TGFβ is a master regulator of radiation therapy-induced antitumor immunity
Vanpouille-Box, C., Diamond, J. M., Pilones, K. A., Zavadil, J., Babb, J. S., Formenti, S. C., Barcellos-Hoff, M. H., & Demaria, S. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3511 · Cited by 514
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
Herrera, F. G., Bourhis, J., & Coukos, G. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 509
Filatenkov, A., Baker, J., Mueller, A. M. S., Kenkel, J., Ahn, G.-O., Dutt, S., Zhang, N., Kohrt, H., Jensen, K., Dejbakhsh-Jones, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2824 · Cited by 474
Abscopal effect of radiotherapy combined with immune checkpoint inhibitors
Liu, Y., Dong, Y., Kong, L., Shi, F., Zhu, H., & Yu, J. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0647-8 · Cited by 447
Radiotherapy and the Tumor Stroma: The Importance of Dose and Fractionation
Hellevik, T., & Martinez-Zubiaurre, I. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00001 · Cited by 442
Abscopal effects of radiation therapy: A clinical review for the radiobiologist
Siva, S., MacManus, M. P., Martin, R. F., & Martin, O. A. (2015) · Cancer Letters · doi:10.1016/j.canlet.2013.09.018 · Cited by 441
Mechanisms regulating T-cell infiltration and activity in solid tumors
Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369
Marciscano, A. E., Ghasemzadeh, A., Nirschl, T. R., Theodros, D., Kochel, C. M., Francica, B. J., Muroyama, Y., Anders, R. A., Sharabi, A. B., Velarde, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3427 · Cited by 335
Radiation as an immunological adjuvant: current evidence on dose and fractionation
Demaria, S., & Formenti, S. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00153 · Cited by 332
The biology and treatment of oligometastatic cancer
Reyes, D. K., & Pienta, K. J. (2015) · Oncotarget · doi:10.18632/oncotarget.3455 · Cited by 320
Radiation and immunotherapy: a synergistic combination
Kalbasi, A., June, C. H., Haas, N., & Vapiwala, N. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69219 · Cited by 284
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Apetoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 280
Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend
Locy, H., de Mey, S., de Mey, W., De Ridder, M., Thielemans, K., & Maenhout, S. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02909 · Cited by 279
Immune control by amino acid catabolism during tumorigenesis and therapy
Lemos, H., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0106-z · Cited by 274
The Effect of Radiation on the Immune Response to Cancers
Park, B., Yee, C., & Lee, K.-M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15010927 · Cited by 272
Han, S., Wang, W., Wang, S., Yang, T., Zhang, G., Wang, D., Ju, R., Lu, Y., Wang, H., & Wang, L. (2021) · Theranostics · doi:10.7150/thno.50928 · Cited by 271
Lim, J. Y. H., Gerber, S. A., Murphy, S. P., & Lord, E. M. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1506-7 · Cited by 257
Self-citationImmunological Mechanisms Underneath the Efficacy of Cancer Therapy
Galluzzi, L., Zitvogel, L., & Kroemer, G. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0197 · Cited by 175
Irradiation and immunotherapy: From concept to the clinic
Salama, A. K. S., Postow, M. A., & Salama, J. K. (2016) · Cancer · doi:10.1002/cncr.29889 · Cited by 85
Murthy, A., Gerber, S. A., Koch, C. J., & Lord, E. M. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900017 · Cited by 36
Self-citationGaire, B., Padmanabhan, S., Zou, Y., Uddin, M. M., Reddy, S. U., & Vancurova, I. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13624 · Cited by 10
Metadata
- Authors
- Lugade, A. A., Sorensen, E. W., Gerber, S. A., Moran, J. P., Frelinger, J. G., & Lord, E. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-01
- Volume
- 180
- Issue
- 5
- Pages
- 3132-3139
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1839872679
- Cited by
- 485
- References
- 49
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.